World Health Organization Sounds Warning Over Acute Scarcity of Obesity Medications

Less than 10% of individuals eligible to benefit from obesity jabs such as Wegovy are able to get them, warns the WHO as it publishes its first advice on the therapies.

With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for broader and more equitable availability to these injectable treatments.

Per projections, more than two billion are projected to be obese by 2030 without intervention.

"The latest guidelines acknowledges that obesity is a chronic disease that can be treated with comprehensive and continuous care," stated its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are significant obstacles to widespread access to the jabs that can aid individuals in losing substantial body mass, notes the agency.

Skinny Jab Scarcity

Even in the current best projected scenario, the supply of such drugs could only cover about 100 million people – fewer than 10% of the global need, as stated by the health organization.

The guideline urges nations and manufacturers to expand access, through strategies like voluntary licensing.

A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.

The Way Obesity Injections Operate

The injections replicate a biological compound to slow digestion, suppress the appetite and enhance satiety so users reduce food intake.

Individuals typically start to lose weight after several weeks of commencing the weekly injections.

Research suggests patients may regain a significant portion within a year of halting the treatment, as their normal hunger resume.

To be above a healthy weight increases your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and specific cancers.

Obesity impacts individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.